FDA Approves Citrate-Free High-Concentration Humira Biosimilar Hadlima
August 18th 2022Adalimumab-bwwd is a tumor necrosis factor blocker indicated for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn disease, ulcerative colitis, and plaque psoriasis.
Read More
FDA Approves Zynteglo for Patients with Beta-thalassemia Requiring Regular Blood Transfusions
August 17th 2022Zynteglo was approved for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions after safety and efficacy were demonstrated in clinical trials.
Read More